Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

2.6K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

7.7K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

469
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
469
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytotoxic CD4+ T cells across aging: a conceptual framework for health, protection, pathology, and age-associated diseases.

International immunology·2026
Same author

The CCL20-CCR6 axis predominantly drives IL-17-mediated psoriasis while modestly contributing to papain-induced type 2 inflammation.

International immunology·2026
Same author

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

From legacy subsets to auditable descriptors: implementing the 2025 T-cell nomenclature guidelines for inflammatory skin diseases.

The British journal of dermatology·2026
Same author

Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.

The Journal of dermatological treatment·2026

Related Experiment Video

Updated: Sep 15, 2025

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

5.6K

Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL-13.

Li Fang Koh1, Muhammad Jasrie Firdaus1, Yohei Natsuaki1

  • 1A*STAR Skin Research Labs (A*SRL), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.

Experimental Dermatology
|July 18, 2025
PubMed
Summary

Ruxolitinib effectively reduced inflammation and itching in atopic dermatitis (AD) models. The drug improved skin barrier function by downregulating IL-13, supporting its clinical efficacy in AD patients.

Keywords:
JAK/STATMC903atopic dermatitisreconstructed human skinruxolitinibskin explants

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

Related Experiment Videos

Last Updated: Sep 15, 2025

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues
08:06

Y-27632 Enriches the Yield of Human Melanocytes from Adult Skin Tissues

Published on: July 8, 2020

5.6K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

7.6K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a common inflammatory skin condition with impaired barrier function and immune dysregulation.
  • Ruxolitinib, a Janus kinase (JAK) inhibitor, is an emerging pharmaceutical therapy for AD.

Purpose of the Study:

  • To evaluate the efficacy of ruxolitinib in mitigating AD-related symptoms using both mouse and human skin models.
  • To investigate the molecular mechanisms underlying ruxolitinib's effects on skin barrier integrity and inflammation.

Main Methods:

  • MC903/ruxolitinib-treated mice were used to assess ear swelling, histology, pruritus, biomarkers, and immune cells.
  • Immunohistochemistry and transcriptome analysis were performed on cytokine-treated reconstructed human skin (RHS) and human skin explants treated with ruxolitinib.

Main Results:

  • Ruxolitinib treatment reduced inflammation, ear swelling, and pruritus in mice, with decreased T cells and IL-13.
  • Transcriptome analysis showed increased STAT3 and decreased FLG in cytokine-treated RHS.
  • Ruxolitinib-treated human skin explants displayed increased expression of skin barrier genes (FLG, FLG2, LOR) and decreased IL13RA1.

Conclusions:

  • Ruxolitinib effectively reduces inflammation and pruritus in AD models by downregulating IL-13 and enhancing skin barrier proteins.
  • Findings align with clinical data showing reduced SCORAD and pruritus in AD patients treated with ruxolitinib.